Literature DB >> 32590316

Mechanisms of immune escape in the cancer immune cycle.

Sha Tang1, Qian Ning2, Ling Yang1, Zhongcheng Mo3, Shengsong Tang4.   

Abstract

Cancer is a critical issue globally with high incidence and mortality, imposing great burden on the society. Although great progress has been made in immunotherapy based on immune checkpoint, only a subset of patients responds to this treatment, suggesting that cancer immune evasion is still a major barrier in current immunotherapy. There are a series of factors contributing to immune evasion despite in an immunocompetent environment. Given that these factors are involved in different steps of the cancer immune cycle. In this review, we discuss the mechanisms of immune escape in each step of the cancer immune cycle and then present therapeutic strategies for overcoming immune escape, with the potential to better understand the determinants of immune escape and make anti-tumor immunity more effective.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer immune cycle; Immune checkpoint; Immune escape; Immunotherapy

Mesh:

Substances:

Year:  2020        PMID: 32590316     DOI: 10.1016/j.intimp.2020.106700

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  23 in total

1.  Therapeutic Effect of Catgut Implantation at Acupoint in a Mouse Model of Hepatocellular Carcinoma by Suppressing Immune Escape.

Authors:  Shi-Hua Xu; Hao-Xuan Luo; Bi-Jun Huang; Ling Yu; Shao-Ju Luo; Hao Hu; Yan Li; Xiao-Tong Lin; Zhi-Rui Cao; Yuan-Jiang Deng; Shi-Jun Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-08       Impact factor: 2.629

2.  Optimization of whole-cell vaccines with CpG/αOX40/cGAMP to strengthen the anti-tumor response of CD4+ T cells in melanomas.

Authors:  Xuedan Du; Jinting Wu; Ye Zhao; Bin Wang; Xiaobo Ding; Qiuyan Lin; Yingyu Chen; Jinduo Zhao; Lixiao Liu; Xiaolu Mao; Zhen Fang; Chunhong Zhang; Wenfeng Li
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-24       Impact factor: 4.322

3.  A novel risk model based on immune response predicts clinical outcomes and characterizes immunophenotypes in triple-negative breast cancer.

Authors:  Xunxi Lu; Zongchao Gou; Luoting Yu; Hong Bu
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

4.  Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model.

Authors:  Tove Selvin; Erik Fasterius; Malin Jarvius; Mårten Fryknäs; Rolf Larsson; Claes R Andersson
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

5.  Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection.

Authors:  Long-Bin Jeng; Tsai-Chung Li; Shih-Chao Hsu; Chiao-Fang Teng
Journal:  Viruses       Date:  2022-06-20       Impact factor: 5.818

Review 6.  Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.

Authors:  Evangelos Koustas; Eleni-Myrto Trifylli; Panagiotis Sarantis; Nikolaos Papadopoulos; Eleni Karapedi; Georgios Aloizos; Christos Damaskos; Nikolaos Garmpis; Anna Garmpi; Kostas A Papavassiliou; Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

7.  Design, Synthesis, and Evaluation of PD-1/PD-L1 Antagonists Bearing a Benzamide Scaffold.

Authors:  Lu Lu; Zhihao Qi; Tianyu Wang; Xiangyu Zhang; Kuojun Zhang; Kaizhen Wang; Yao Cheng; Yibei Xiao; Zheng Li; Sheng Jiang
Journal:  ACS Med Chem Lett       Date:  2022-03-29       Impact factor: 4.632

8.  The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy.

Authors:  Fei Wang; Lei Zhou; Na Chen; Xiaoming Li
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

Review 9.  Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?

Authors:  Shiyi Zuo; Jiaxuan Song; Jingxuan Zhang; Zhonggui He; Bingjun Sun; Jin Sun
Journal:  Theranostics       Date:  2021-06-01       Impact factor: 11.556

Review 10.  Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.

Authors:  Ya-Nan Pi; Wen-Cai Qi; Bai-Rong Xia; Ge Lou; Wei-Lin Jin
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.